RE: Dispute a Total Distraction2 Jul 2021 18:03
PathFlow® SARS-CoV-2 Antigen is a professional and home use LFT for the detection of SARS-CoV-2 antigens using non-invasive anterior nasal swab samples to provide a result in approximately 15 minutes. Novacyt has been working with a partner to develop this test, which is able to detect the virus regardless of current known mutations. The Company intends to launch the test as CE-IVD before the end of Q2 2021 and expects it to complement Novacyt's established position in COVID-19 PCR testing. As the market for COVID-19 testing continues to develop, the Directors believe this product could add significant revenues for Novacyt.
Rns on 23rd of April , Bladesharp in now sipping champagne flushed with success.)))
Only came on to say the bourse got confused and had 60,000+ buy at the death , have a good weekend all.